ORIN.F logo

Orion Oyj OTCPK:ORIN.F Stock Report

Last Price

US$47.16

Market Cap

US$5.0b

7D

0%

1Y

1.1%

Updated

22 Apr, 2024

Data

Company Financials +

ORIN.F Stock Overview

Develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. More details

ORIN.F fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance2/6
Financial Health5/6
Dividends4/6

Orion Oyj Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Orion Oyj
Historical stock prices
Current Share Price€47.16
52 Week High€47.16
52 Week Low€37.00
Beta0.35
11 Month Change0%
3 Month Changen/a
1 Year Change1.09%
33 Year Changen/a
5 Year Change26.43%
Change since IPO90.55%

Recent News & Updates

Recent updates

Shareholder Returns

ORIN.FUS PharmaceuticalsUS Market
7D0%-6.0%-2.1%
1Y1.1%9.6%30.2%

Return vs Industry: ORIN.F underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.

Return vs Market: ORIN.F underperformed the US Market which returned 19.3% over the past year.

Price Volatility

Is ORIN.F's price volatile compared to industry and market?
ORIN.F volatility
ORIN.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: ORIN.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ORIN.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19173,632Liisa Hurmewww.orion.fi

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.

Orion Oyj Fundamentals Summary

How do Orion Oyj's earnings and revenue compare to its market cap?
ORIN.F fundamental statistics
Market capUS$4.95b
Earnings (TTM)US$230.93m
Revenue (TTM)US$1.27b

21.4x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ORIN.F income statement (TTM)
Revenue€1.19b
Cost of Revenue€531.90m
Gross Profit€657.80m
Other Expenses€441.00m
Earnings€216.80m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)1.54
Gross Margin55.29%
Net Profit Margin18.22%
Debt/Equity Ratio21.6%

How did ORIN.F perform over the long term?

See historical performance and comparison

Dividends

4.9%

Current Dividend Yield

105%

Payout Ratio